Mexico In her latest strategy to tackle Mexico’s persistent medicine shortages – a struggle inherited from predecessor López Obrador – President Claudia Sheinbaum has issued a decree that seeks to attract foreign biopharma investment. By promising international companies a better chance at winning government tenders, Sheinbaum hopes to increase domestic manufacturing,…
Denmark Flemming Sonne, CEO of Amgros, Denmark’s central pharmaceutical procurement organization for hospital medicines, outlines the organisation’s evolving role in ensuring affordable and sustainable access to medicines. In this interview, Sonne discusses Denmark’s forward-thinking approach to supply chain resilience, the integration of ATMPs and innovative access models, and the increasing convergence…
Saudi Arabia Saudi Arabia’s Local Content & Government Procurement Authority (LCGPA) aims to enhance local economic growth by increasing domestic expenditure through strategic government procurement. The organization’s mission is to promote knowledge-based policies and tools, ensuring that local content development is prioritized across all sectors, particularly healthcare, in alignment with Saudi Vision…
Saudi Arabia NUPCO, the centralised procurement body for healthcare products to Saudi Arabia’s government health sector, has embarked on a major digital transformation initiative over the past three years. CEO Fahad Al Shebel outlines its scope and impact, NUPCO’s role in localising insulin manufacturing in Saudi Arabia, and how it is enhancing…
Egypt The head of the Pharmaceutical Chamber of the Federation of Egyptian Industries, Gamal El-Leithy, shares his view on the positive developments driving the growth of Egypt’s pharma market, including the creation of an independent regulatory body and a procurement agency. In addition, he analyses the country’s response to the COVID-19…
Egypt The head of the Egyptian Unified Procurement Authority (UPA), Major General Doctor Bahaa El Din Zeidan, outlines the agency’s view on tenders, emphasizing their vision to secure the highest quality at the best price for Egyptian patients, and analyses the country’s healthcare transformation. In addition, he argues in favour of…
Saudi Arabia Saudi Arabia’s response to COVID-19 stands up well to international comparisons in both the MENA region and globally. In recent conversation with PharmaBoardroom, Fahad Al Shebel, CEO of national medicine procurement body NUPCO, outlines some of the fundamentals behind this success story. Extreme, But Effective, Measures Saudi Arabia took…
Saudi Arabia Fahad Al Shebel is CEO of NUPCO, the centralised procurement body for healthcare products to Saudi Arabia’s government health sector. In a wide-ranging interview, Al Shebel describes NUPCO’s evolution to today provide a broad range of services, its central role in fighting the COVID-19 pandemic, digitalization initiatives, and how its…
Europe In the wake of the 2021 United Nations Climate Change Conference (COP26), sustainability is once more a hot-button issue across all industries, including pharma. Here, Marco Rauland, vice president global market access & pricing strategic planning at Merck Group, casts his eye across Europe to assess how sustainability criteria are…
Denmark Flemming Sonne of Denmark’s public hospital medicine procurement body Amgros outlines the scope and mission of the group, how its remit has increased to include security of supply in the wake of the COVID-19 pandemic, and why international collaboration and knowledge-sharing is crucial, especially in the new era of complex…
Saudi Arabia As part of Saudi Arabia’s ambitious ‘Vision 2030’ economic transformation plan, the country has centralised the public procurement of medications through the National Unified Procurement Company for Medical Supplies (NUPCO). Here, some of the Kingdom’s most prominent pharma leaders weigh in on the impact of this new system for their…
China Since the Chinese government unrolled an unprecedented volume-based procurement initiative for essential drugs used in the public hospital system in November 2018 in a bid to curb unsustainable healthcare expenditures, domestic and foreign drug manufacturers have been forced into an increasingly cutthroat race to the bottom, at least for the…
See our Cookie Privacy Policy Here